Notice Information
Notice Title
Glo-BNHL international clinical site monitoring
Notice Description
Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work.
Lot Information
Lot 1
Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work. The preferred vendor for clinical site monitoring is Premier Research. Premier were selected in 2020 to work on the Far-RMS trial after going to tender because they most closely fulfilled our needs as detailed below: They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes They have extensive experience in haemato-oncology projects operating globally (194 projects to date) They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies) They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide
Procurement Information
The preferred vendor for clinical site monitoring is Premier Research. They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes They have extensive experience in haemato-oncology projects operating globally (194 projects to date) They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies) They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide When deciding upon a partner to work with us on Glo-BNHL, we felt the expertise detailed above, as well as the following other considerations, made Premier the right choice for this trial:: Proven expertise in oncology trials, particularly rare disease trials Proven expertise in paediatric trials Proven expertise in global trials Ability to perform interim and follow-up site monitoring visits (and proven experience of doing so) in the following countries: UK, Europe (Austria, Belgium, France, Germany, Italy, Netherlands, NOPHO (Sweden, Norway, Denmark, Finland), Poland, Spain), USA, Canada, Australia, New Zealand and Israel Ability to perform interim and follow-up site monitoring visits across 45 sites Ability to support the volume of data that will be produced by 30 patients per treatment arm according to the treatment schedule outlined in the Glo-BNHL protocol Ability to work with the procedures and systems of the CRCTU at the University of Birmingham Ability to develop a monitoring plan in conjunction with the Glo-BNHL trial management team
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-042bb3
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/000664-2024
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Limited
- Procurement Method Details
- Negotiated without publication of a contract notice
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
73 - Research and development services and related consultancy services
-
- CPV Codes
73000000 - Research and development services and related consultancy services
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 9 Jan 20242 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 9 Jan 20242 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Not Specified
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- THE UNIVERSITY OF BIRMINGHAM
- Contact Name
- Kseniya Samsonik
- Contact Email
- k.samsonik@bham.ac.uk
- Contact Phone
- Not specified
Buyer Location
- Locality
- BIRMINGHAM
- Postcode
- B15 2TT
- Post Town
- Birmingham
- Country
- England
-
- Major Region (ITL 1)
- TLG West Midlands (England)
- Basic Region (ITL 2)
- TLG3 West Midlands
- Small Region (ITL 3)
- TLG31 Birmingham
- Delivery Location
- TLG31 Birmingham
-
- Local Authority
- Birmingham
- Electoral Ward
- Edgbaston
- Westminster Constituency
- Birmingham Edgbaston
Further Information
Notice URLs
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-042bb3-2024-01-09T15:08:28Z",
"date": "2024-01-09T15:08:28Z",
"ocid": "ocds-h6vhtk-042bb3",
"initiationType": "tender",
"tender": {
"id": "SC12209/24",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Glo-BNHL international clinical site monitoring",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "73000000",
"description": "Research and development services and related consultancy services"
},
"mainProcurementCategory": "services",
"description": "Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work.",
"lots": [
{
"id": "1",
"description": "Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work. The preferred vendor for clinical site monitoring is Premier Research. Premier were selected in 2020 to work on the Far-RMS trial after going to tender because they most closely fulfilled our needs as detailed below: They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes They have extensive experience in haemato-oncology projects operating globally (194 projects to date) They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies) They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide",
"hasOptions": false
}
],
"items": [
{
"id": "1",
"deliveryAddresses": [
{
"region": "UKG31"
}
],
"relatedLot": "1"
}
],
"procurementMethod": "limited",
"procurementMethodDetails": "Negotiated without publication of a contract notice",
"procurementMethodRationaleClassifications": [
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_TECHNICAL",
"description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
}
],
"procurementMethodRationale": "The preferred vendor for clinical site monitoring is Premier Research. They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes They have extensive experience in haemato-oncology projects operating globally (194 projects to date) They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies) They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide When deciding upon a partner to work with us on Glo-BNHL, we felt the expertise detailed above, as well as the following other considerations, made Premier the right choice for this trial:: Proven expertise in oncology trials, particularly rare disease trials Proven expertise in paediatric trials Proven expertise in global trials Ability to perform interim and follow-up site monitoring visits (and proven experience of doing so) in the following countries: UK, Europe (Austria, Belgium, France, Germany, Italy, Netherlands, NOPHO (Sweden, Norway, Denmark, Finland), Poland, Spain), USA, Canada, Australia, New Zealand and Israel Ability to perform interim and follow-up site monitoring visits across 45 sites Ability to support the volume of data that will be produced by 30 patients per treatment arm according to the treatment schedule outlined in the Glo-BNHL protocol Ability to work with the procedures and systems of the CRCTU at the University of Birmingham Ability to develop a monitoring plan in conjunction with the Glo-BNHL trial management team"
},
"awards": [
{
"id": "000664-2024-1",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-COH-04671020",
"name": "Premier Research Group Limited"
}
]
}
],
"parties": [
{
"id": "GB-COH-RC000645",
"name": "THE UNIVERSITY OF BIRMINGHAM",
"identifier": {
"legalName": "THE UNIVERSITY OF BIRMINGHAM",
"id": "RC000645",
"scheme": "GB-COH"
},
"address": {
"streetAddress": "Edgbaston",
"locality": "BIRMINGHAM",
"region": "UKG31",
"postalCode": "B152TT",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Kseniya Samsonik",
"email": "K.Samsonik@bham.ac.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "http://www.birmingham.ac.uk",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "09",
"description": "Education"
}
]
}
},
{
"id": "GB-COH-04671020",
"name": "Premier Research Group Limited",
"identifier": {
"legalName": "Premier Research Group Limited",
"id": "04671020",
"scheme": "GB-COH"
},
"address": {
"locality": "Reading",
"region": "UKJ11",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-84837",
"name": "University Of Birmingham",
"identifier": {
"legalName": "University Of Birmingham"
},
"address": {
"locality": "Edgbaston",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"id": "GB-COH-RC000645",
"name": "THE UNIVERSITY OF BIRMINGHAM"
},
"contracts": [
{
"id": "000664-2024-1",
"awardID": "000664-2024-1",
"status": "active",
"value": {
"amount": 0.01,
"currency": "GBP"
},
"dateSigned": "2024-01-09T00:00:00Z"
}
],
"language": "en"
}